Significant Role for Fas in the Pathogenesis of Autoimmune Diabetes

Programmed cell death represents an important pathogenic mechanism in various autoimmune diseases. Type I diabetes mellitus (IDDM) is a T cell-dependent autoimmune disease resulting in selective destruction of the β cells of the islets of Langerhans. β cell apoptosis has been associated with IDDM onset in both animal models and newly diagnosed diabetic patients. Several apoptotic pathways have been implicated in β cell destruction, including Fas, perforin, and TNF-α. Evidence for Fas-mediated lysis of β cells in the pathogenesis of IDDM in nonobese diabetic (NOD) mice includes: 1) Fas-deficient NOD mice bearing the lpr mutation (NOD-lpr/lpr) fail to develop IDDM; 2) transgenic expression of Fas ligand (FasL) on β cells in NOD mice may result in accelerated IDDM; and 3) irradiated NOD-lpr/lpr mice are resistant to adoptive transfer of diabetes by cells from NOD mice. However, the interpretation of these results is complicated by the abnormal immune phenotype of NOD-lpr/lpr mice. Here we present novel evidence for the role of Fas/FasL interactions in the progression of NOD diabetes using two newly derived mouse strains. We show that NOD mice heterozygous for the FasL mutation gld, which have reduced functional FasL expression on T cells but no lymphadenopathy, fail to develop IDDM. Further, we show that NOD-lpr/lpr mice bearing the scid mutation (NOD-lpr/lpr-scid/scid), which eliminates the enhanced FasL-mediated lytic activity induced by Fas deficiency, still have delayed onset and reduced incidence of IDDM after adoptive transfer of diabetogenic NOD spleen cells. These results provide evidence that Fas/FasL-mediated programmed cell death plays a significant role in the pathogenesis of autoimmune diabetes.

[1]  A. Cross,et al.  Dual Role for Fas Ligand in the Initiation of and Recovery from Experimental Allergic Encephalomyelitis , 1999, The Journal of experimental medicine.

[2]  T. Mak,et al.  TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. , 1999, Journal of immunology.

[3]  T. Utsugi,et al.  Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. , 1999, The Journal of clinical investigation.

[4]  J. Katz,et al.  In Autoimmune Diabetes the Transition from Benign to Pernicious Insulitis Requires an Islet Cell Response to Tumor Necrosis Factor α , 1999, The Journal of experimental medicine.

[5]  R. Rajotte,et al.  Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. , 1999, Diabetes.

[6]  Z. Wang,et al.  Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases , 1999, Nature Medicine.

[7]  A. Strasser,et al.  Mechanisms of beta cell death in diabetes: a minor role for CD95. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Marumo,et al.  The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats. , 1998, Journal of immunology.

[9]  R. Flavell,et al.  Local expression of TNFalpha in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. , 1998, Immunity.

[10]  F. Shanahan,et al.  Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer , 1998, The Journal of pathology.

[11]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. , 1998, The Journal of clinical investigation.

[12]  W. Suarez-Pinzon,et al.  Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. , 1998, Biochemical pharmacology.

[13]  S. Sakoda,et al.  Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. , 1998, Molecular immunology.

[14]  M. Monden,et al.  Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts , 1998, Diabetologia.

[15]  H. Jun,et al.  Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. , 1998, Autoimmunity.

[16]  C. Benoist,et al.  Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Stassi,et al.  Nitric Oxide Primes Pancreatic β Cells for Fas-mediated Destruction in Insulin-dependent Diabetes Mellitus , 1997, The Journal of experimental medicine.

[18]  R. Zinkernagel,et al.  Reduced Incidence and Delayed Onset of Diabetes in Perforin-deficient Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.

[19]  A. Cross,et al.  Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. , 1997, Journal of immunology.

[20]  V. Kuchroo,et al.  Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. , 1997, Journal of immunology.

[21]  Y. Matsuzawa,et al.  Requirement of Fas for the Development of Autoimmune Diabetes in Nonobese Diabetic Mice , 1997, The Journal of experimental medicine.

[22]  P. Cohen,et al.  Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Corbett,et al.  Interferon-γ Increases the Sensitivity of Islets of Langerhans for Inducible Nitric-oxide Synthase Expression Induced by Interleukin 1* , 1997, The Journal of Biological Chemistry.

[24]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[25]  D. Allan,et al.  Apoptosis Is the Mode of β-Cell Death Responsible for the Development of IDDM in the Nonobese Diabetic (NOD) Mouse , 1997, Diabetes.

[26]  H. Maeda,et al.  Polymorphism of murine Fas ligand that affects the biological activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Nagata,et al.  Essential roles of the Fas ligand in the development of hepatitis , 1997, Nature Medicine.

[28]  C. Janeway,et al.  The Role of Fas in Autoimmune Diabetes , 1997, Cell.

[29]  C. Benoist,et al.  Cell Death Mediators in Autoimmune Diabetes—No Shortage of Suspects , 1997, Cell.

[30]  T. Saito,et al.  Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Todaro,et al.  Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis , 1997, Science.

[32]  M. V. von Herrath,et al.  Interferon-γ Is Essential for Destruction of β Cells and Development of Insulin-dependent Diabetes Mellitus , 1997, The Journal of experimental medicine.

[33]  L. Notarangelo,et al.  Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. , 1997, Blood.

[34]  P. Vassalli,et al.  Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55 , 1997, European journal of immunology.

[35]  M. Oldstone,et al.  Interferon-g Is Essential for Destruction of b Cells and Development of Insulin-dependent Diabetes Mellitus , 1997 .

[36]  S. Nagata.  Fas ligand and immune evasion , 1996, Nature Medicine.

[37]  K. Sullivan,et al.  Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. , 1996, The New England journal of medicine.

[38]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[39]  C. Janeway,et al.  Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells , 1996, The Journal of experimental medicine.

[40]  K. Yamada,et al.  Mouse islet cell lysis mediated by interleukin-1-induced Fas , 1996, Diabetologia.

[41]  L. Matis,et al.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. , 1996, The Journal of clinical investigation.

[42]  P. Schur,et al.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.

[43]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[44]  John A Todd,et al.  Genetic Analysis of Autoimmune Disease , 1996, Cell.

[45]  R. Tisch,et al.  Insulin-Dependent Diabetes Mellitus , 1996, Cell.

[46]  M. Todaro,et al.  Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human beta-cells sorted by flow-cytometry and cultured in vitro. , 1995, Transplantation proceedings.

[47]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[48]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.

[49]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[50]  T. Ogihara,et al.  Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. , 1995, The Journal of clinical investigation.

[51]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[52]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[53]  E. Lacy,et al.  Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome , 1995, The Journal of experimental medicine.

[54]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[55]  J. Todd,et al.  Genetic control of autoimmune diabetes in the NOD mouse. , 1995, Annual review of immunology.

[56]  J. Inazawa,et al.  Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.

[57]  R. Tisch,et al.  Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process , 1994, The Journal of experimental medicine.

[58]  D. Eizirik,et al.  TNF-α and IFN-γ potentiate the deleterious effects of IL-1β on mouse pancreatic islets mainly via generation of nitric oxide , 1994 .

[59]  M R Alderson,et al.  The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. , 1994, Immunity.

[60]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[61]  M. A. Bowman,et al.  Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. , 1994, Immunology today.

[62]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[63]  N. Copeland,et al.  The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. , 1992, Journal of immunology.

[64]  V. Fadok,et al.  Apoptosis and programmed cell death in immunity. , 1992, Annual review of immunology.

[65]  K. Lafferty,et al.  Involvement of O2 radicals in ‘autoimmune’ diabetes , 1989, Immunology and cell biology.

[66]  L. Harrison,et al.  IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to murine islets of Langerhans. , 1988, Journal of immunology.

[67]  N. Sarvetnick,et al.  Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma , 1988, Cell.

[68]  J. Nerup,et al.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. , 1987, Journal of immunology.

[69]  K. Lafferty,et al.  Combined Treatment With Nicotinamide and Desferrioxamine Prevents Islet Allograft Destruction in NOD Mice , 1986, Diabetes.

[70]  L. Wicker,et al.  Transfer of Autoimmune Diabetes Mellitus with Splenocytes from Nonobese Diabetic (NOD) Mice , 1986, Diabetes.

[71]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[72]  P. Kelleher,et al.  Insulin-dependent? , 1985, The Lancet.